interact
enhanc
neutral
activ
three
monoclon
antibodi
mab
spike
protein
felin
infecti
periton
viru
fipv
strain
determin
use
felin
macrophag
high
mab
concentr
three
mab
complet
inhibit
fipv
infect
c
howev
two
enhanc
fipv
infect
either
mab
concentr
reaction
temperatur
lower
mab
also
exert
immedi
infectivityenhanc
activ
min
reaction
min
neutral
activ
observ
mab
consist
show
neutral
activ
regardless
reaction
condit
competit
sera
cat
experiment
infect
fipv
strain
felin
enter
coronaviru
strain
show
two
epitop
recogn
mab
mab
respect
also
recogn
natur
host
felin
infecti
periton
viru
fipv
member
coronaviru
group
caus
chronic
progress
immunemedi
diseas
natur
host
antibodi
fipv
shown
acceler
rate
fipv
infect
diseas
onset
cat
cat
immun
close
relat
coronavirus
felin
enter
coronaviru
fecv
also
sensit
exposur
virul
fipv
phenomena
thought
caus
mechan
similar
dengu
shock
syndrom
macrophag
known
one
target
cell
fipv
dengu
viru
infect
previous
report
fipv
infect
felin
alveolar
macrophag
enhanc
monoclon
antibodi
mab
peplom
spike
protein
transmembran
protein
antibodydepend
enhanc
ade
complet
offset
reduc
pretreat
mab
protein
f
ab
fragment
mab
use
olsen
et
al
corapi
et
al
recent
support
find
show
enhanc
fipv
infect
primari
felin
periton
macrophag
mab
viral
protein
mani
instanc
neutral
mab
abl
induc
ade
demonstr
direct
relationship
neutral
enhanc
describ
paper
relationship
neutral
enhanc
activ
mab
recogn
three
distinct
epitop
protein
recov
cell
centrifug
wash
three
time
hbss
resuspend
growth
medium
eagl
minimum
essenti
medium
contain
leibovitz
medium
fetal
calf
serum
unit
per
ml
penicillin
ml
streptomycin
final
concentr
x
cellsml
one
ml
cell
suspens
ad
well
multipl
contain
steril
glass
cover
slip
incub
c
hr
cell
cover
slip
wash
hbss
incub
growth
medium
addit
hr
c
wash
hbss
adher
cell
thu
obtain
use
macrophag
experi
indirect
fluoresc
antibodi
assay
ifa
carri
describ
previous
neutral
nt
test
also
carri
describ
previous
antibodydepend
enhanc
ade
assay
fipv
infect
carri
follow
equal
amount
mab
viral
suspens
allow
react
hr
c
c
c
mixtur
inocul
ml
volum
well
multipl
cultur
macrophag
incub
day
adsorpt
c
hr
follow
wash
hbss
ml
growth
medium
ad
plate
incub
c
hr
incub
cover
slip
remov
examin
ifa
percentag
ade
obtain
follow
formula
percent
ade
b
b
x
rate
posit
ifa
presenc
antibodi
b
rate
posit
ifa
absenc
antibodi
competit
enzymelink
immunosorb
assay
elisa
antigen
prepar
fipv
strain
grown
cell
cultur
antigen
purifi
infecti
cultur
fluid
method
previous
describ
cat
serum
dilut
pb
contain
calf
serum
ad
microelisa
plate
coat
viral
antigen
plate
incub
c
hr
plate
wash
pb
contain
three
time
peroxidaseconjug
mab
optim
dilut
pb
contain
calf
serum
ad
incub
c
min
well
receiv
substrat
solut
plate
incub
c
min
dark
room
substrat
solut
prepar
dissolv
ophenylenediamin
dihydrochlorid
concentr
mgml
citric
buffer
ph
ad
ii
incub
reaction
stop
n
solut
optic
densiti
od
nm
measur
percent
inhibit
calcul
formula
ab
ba
od
dilut
buffer
b
od
test
serum
interact
neutral
enhanc
activ
mab
neutral
nt
titer
nt
titer
nt
titer
protein
fipv
strain
studi
felin
alveolar
macrophag
three
undilut
mab
complet
neutral
infect
fipv
upon
preincub
mab
viru
hr
c
fig
howev
reaction
condit
mab
dilut
enhanc
fipv
infect
mab
higher
enhanc
activ
enhanc
activ
mab
observ
even
undilut
sampl
reaction
temperatur
mabviru
mixtur
lower
c
c
c
c
even
undilut
mab
neutral
activ
instead
exhibit
weak
enhanc
activ
contrast
mab
neutral
activ
reaction
condit
employ
except
neutral
activ
decreas
lower
reaction
temperatur
undilut
mab
viru
ad
macrophag
cultur
immedi
min
min
reaction
c
strong
enhanc
activ
observ
mab
fig
enhanc
strong
neutral
observ
mab
viru
allow
react
least
min
weak
enhanc
activ
observ
mab
min
reaction
fig
thereaft
activ
gradual
lost
neutral
activ
becam
detect
mab
remain
abl
neutral
viru
infect
throughout
reaction
period
min
test
fig
competit
elisa
perform
determin
whether
epitop
recogn
mab
recogn
cat
experiment
infect
fipv
fecv
mab
compet
sera
fipvand
fecvinfect
cat
fig
competit
increas
increas
nt
titer
serum
gener
sera
fipvinfect
cat
compet
effect
mab
fecvinfect
cat
sera
compet
effect
epitop
recogn
mab
one
recogin
mab
enhanc
neutral
antibodi
detect
cat
infect
fipv
use
mab
attempt
identifi
epitop
requir
enhanc
neutral
activ
evalu
develop
antibodi
epitop
cat
fipv
infect
identifi
three
distinct
group
mab
fipv
protein
ade
activ
neutral
activ
activ
previou
studi
character
two
monoclon
antibodi
recogn
viral
protein
possess
ade
activ
present
studi
character
three
mab
identifi
three
distinct
epitop
viral
protein
mab
enhanc
neutral
activ
depend
upon
reaction
condit
concentr
reaction
temperatur
reaction
time
suggest
enhanc
event
intermedi
stage
neutral
pathway
mab
exert
neutral
activ
alon
regardless
reaction
condit
inhibit
viru
prolifer
mab
may
exert
adsorpt
virus
cell
howev
mab
allow
react
virus
follow
adsorpt
virus
c
hr
inocul
virus
crfk
cell
cultur
mab
inhibit
viru
infect
data
shown
sinc
mab
recogn
epitop
essenti
neutral
sinc
mab
recogn
epitop
enhanc
epitop
close
relat
neutral
epitop
neutral
may
achiev
steric
hindranc
case
multibond
result
adequ
reaction
sinc
result
obtain
studi
vitro
result
mous
mab
appli
directli
vivo
situat
clear
howev
epitop
recogn
mab
close
relat
defenc
fipv
infect
suggest
fipv
infect
may
prevent
neutral
antibodi
result
competit
elisa
reveal
antibodi
epitop
recogn
mab
rais
fipv
fecvinfect
cat
percent
inhibit
mab
alway
higher
mab
differ
percent
inhibit
mab
mab
remark
late
stage
earli
stage
infect
fecv
straininfect
cat
preexist
heterologu
fecv
immun
often
acceler
enhanc
sever
diseas
caus
inocul
fipv
gimenez
et
al
report
respiratori
syncyti
rs
viru
infect
cell
enhanc
convalesc
sera
patient
rs
viru
infect
vennema
et
al
combin
protein
gene
fipv
vaccinia
viru
cat
immun
recombin
viru
show
protect
challeng
virul
fipv
onset
diseas
acceler
immun
also
clear
result
enhanc
epitop
present
protein
vaccin
without
enhanc
epitop
may
develop
analysi
epitop
recogn
mab
aspect
well
result
present
studi
meaning
